Children with cancer could get easier access to personalized medicines in UK

31 March 2016

Children diagnosed with some of the most aggressive cancers could be able to access more personalized medicines under a new initiative being rolled out in the UK.

Around 400 children with solid tumors across 21 of the UK’s hospitals are to be offered testing for genetic mutations in their tumors, as part a joint initiative between The Institute of Cancer Research, the Royal Marsden NHS Foundation Trust and UK cancer charity Christopher’s Smile.

The testing program is the first stage of a wider aim to eventually test all children with solid tumors in the UK and direct them into clinical trials targeting particular mutations within their tumors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK